CA2531419C - Procede de stabilisation d'un cryoprecipite de proteines plasmatiques destine a etre soumis a un traitement thermique d'inactivation virale - Google Patents
Procede de stabilisation d'un cryoprecipite de proteines plasmatiques destine a etre soumis a un traitement thermique d'inactivation virale Download PDFInfo
- Publication number
- CA2531419C CA2531419C CA2531419A CA2531419A CA2531419C CA 2531419 C CA2531419 C CA 2531419C CA 2531419 A CA2531419 A CA 2531419A CA 2531419 A CA2531419 A CA 2531419A CA 2531419 C CA2531419 C CA 2531419C
- Authority
- CA
- Canada
- Prior art keywords
- proteins
- stabilizing
- viral inactivation
- cryoprecipitate
- subjected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention concerne un procédé d'obtention de protéines cryoprécipitables, comprenant une étape d'inactivation virale par traitement thermique d'un lyophilisat desdites protéines, comportant, avant la mise des protéines sous la forme de lyophilisat, une étape initiale d'ajout, auxdites protéines, d'une formulation stabilisante et solubilisante comprenant un mélange d'arginine, d'au moins un acide aminé hydrophobe et de citrate trisodique. L'invention concerne également un concentré d~au moins une protéine cryoprécipitable comprenant la formulation stabilisante et solubilisante introduite selon le procédé et susceptible d'être destiné à un usage thérapeutique.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR03/08403 | 2003-07-09 | ||
FR0308403A FR2857267B1 (fr) | 2003-07-09 | 2003-07-09 | Formulation stabilisante et solubilisante pour les proteines cryoprecipitables. |
PCT/FR2004/001788 WO2005004901A1 (fr) | 2003-07-09 | 2004-07-08 | Procede de stabilisation d’un cryoprecipite de proteines plasmatiques destine a etre soumis a un traitement thermique d’inactivation virale |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2531419A1 CA2531419A1 (fr) | 2005-01-20 |
CA2531419C true CA2531419C (fr) | 2014-12-23 |
Family
ID=33522899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2531419A Expired - Fee Related CA2531419C (fr) | 2003-07-09 | 2004-07-08 | Procede de stabilisation d'un cryoprecipite de proteines plasmatiques destine a etre soumis a un traitement thermique d'inactivation virale |
Country Status (13)
Country | Link |
---|---|
US (1) | US7727743B2 (fr) |
EP (1) | EP1648496B1 (fr) |
JP (2) | JP4925822B2 (fr) |
AT (1) | ATE546155T1 (fr) |
AU (1) | AU2004255503B2 (fr) |
BR (1) | BRPI0412441A (fr) |
CA (1) | CA2531419C (fr) |
DK (1) | DK1648496T3 (fr) |
ES (1) | ES2382934T3 (fr) |
FR (1) | FR2857267B1 (fr) |
IL (1) | IL172844A (fr) |
PL (1) | PL1648496T3 (fr) |
WO (1) | WO2005004901A1 (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100624013B1 (ko) * | 2004-06-25 | 2006-09-19 | 주식회사 녹십자홀딩스 | 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제 |
US20060019234A1 (en) * | 2004-07-22 | 2006-01-26 | Shanbrom Technologies, Llc | Modern blood banking employing improved cell preservation composition |
FR2874216B1 (fr) | 2004-08-16 | 2006-11-03 | Lab Francais Du Fractionnement | Procede de preparation d'un concentre de facteur von willebrand (fvw) par voie chromatographique et concentre de fvw susceptible d'etre ainsi obtenu |
FR2894831B1 (fr) * | 2005-12-16 | 2008-02-15 | Lab Francais Du Fractionnement | Colle biologique exempte de thrombine et son utilisation comme medicament. |
ES2264403B1 (es) * | 2006-06-22 | 2007-11-01 | Grifols S.A. | Medio de suspension de hematies. |
CA2692165A1 (fr) | 2007-06-25 | 2008-12-31 | Amgen Inc. | Compositions d'agents de liaison specifiques vis-a-vis du facteur de croissance des hepatocytes |
US8349367B2 (en) * | 2007-10-12 | 2013-01-08 | Bakaltcheva Irina B | Freeze-dried plasma formats for the trauma care field |
FR2947181B1 (fr) | 2009-06-26 | 2012-05-04 | Lfb Biotechnologies | Composition de facteur vii |
TW201335181A (zh) * | 2012-01-31 | 2013-09-01 | Kieu Hoang | 55種新發現的蛋白質之序列及其應用 |
WO2018007767A1 (fr) * | 2016-07-06 | 2018-01-11 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Fibrinogène liquide stable |
FR3053592B1 (fr) * | 2016-07-06 | 2020-05-29 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Fibrinogene liquide stable |
FR3061020B1 (fr) * | 2016-12-22 | 2019-05-17 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Composition de fibrinogene humain |
WO2019074886A1 (fr) | 2017-10-09 | 2019-04-18 | Terumo Bct Biotechnologies, Llc | Récipient de lyophilisation et son procédé d'utilisation |
US11609043B2 (en) | 2019-03-14 | 2023-03-21 | Terumo Bct Biotechnologies, Llc | Lyophilization container fill fixture, system and method of use |
WO2023119277A1 (fr) | 2021-12-21 | 2023-06-29 | Omrix Biopharmaceuticals Ltd. | Compositions de fibrinogène hautement solubles |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4623717A (en) * | 1980-03-05 | 1986-11-18 | Miles Laboratories, Inc. | Pasteurized therapeutically active protein compositions |
US4456590B2 (en) | 1981-11-02 | 1989-05-30 | Heat treatment of lyphilized blood clotting factor viii concentrate | |
DE3203775A1 (de) * | 1982-02-04 | 1983-08-11 | Behringwerke Ag, 3550 Marburg | Fibrinogenzubereitung, verfahen zu ihrer herstellungund ihre verwendung |
US4470968A (en) * | 1983-01-13 | 1984-09-11 | Miles Laboratories, Inc. | Pasteurized therapeutically active blood coagulation factor concentrates |
CA1260389A (fr) | 1984-10-10 | 1989-09-26 | Jay A. Levy | Plasma humain, fractions de plasma et composes desdites substances exempt de virus, de bacteries et de retrovirus infectieux |
JPS6289628A (ja) * | 1985-09-11 | 1987-04-24 | Green Cross Corp:The | 人フイブリノゲン製剤の加熱処理法 |
DE3622642A1 (de) * | 1986-07-05 | 1988-01-14 | Behringwerke Ag | Einkomponenten-gewebekleber sowie verfahren zu seiner herstellung |
JPS6419023A (en) * | 1987-04-21 | 1989-01-23 | Green Cross Corp | Heat treatment of fibrinogen and fibrinogen preparation |
DE3729863A1 (de) * | 1987-09-05 | 1989-03-16 | Boehringer Mannheim Gmbh | Stabilisierte erythropoietin-lyophilisate |
FR2632309B1 (fr) | 1988-06-07 | 1990-08-24 | Lille Transfusion Sanguine | Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus |
AU670793B2 (en) * | 1992-04-30 | 1996-08-01 | Alpha Therapeutic Corporation | Improved solubilization and stabilization of factor VIII complex |
DE4242863A1 (de) * | 1992-12-18 | 1994-06-23 | Boehringer Mannheim Gmbh | Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF |
GB9424732D0 (en) * | 1994-12-08 | 1995-02-08 | Common Services Agency | Heat treated blood plasma proteins |
AUPO871997A0 (en) * | 1997-08-25 | 1997-09-18 | Csl Limited | Dried biologically or therapeutically active preparations |
DK1018345T3 (da) * | 1998-06-26 | 2009-03-23 | Otsuka Pharma Co Ltd | Vandoplöselige, törre sammensætninger |
JP2000247903A (ja) * | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
JP2001270900A (ja) * | 2000-03-23 | 2001-10-02 | Nihon Pharmaceutical Co Ltd | フィブリノゲンのウイルス不活化法 |
US6623717B2 (en) | 2001-03-28 | 2003-09-23 | Council Of Scientific And Industrial Research | Process for the preparation of LiBF4 |
JP2003055257A (ja) * | 2001-08-10 | 2003-02-26 | Nihon Pharmaceutical Co Ltd | 安定な血液凝固第xiii因子製剤 |
-
2003
- 2003-07-09 FR FR0308403A patent/FR2857267B1/fr not_active Expired - Lifetime
-
2004
- 2004-07-08 DK DK04767620.0T patent/DK1648496T3/da active
- 2004-07-08 PL PL04767620T patent/PL1648496T3/pl unknown
- 2004-07-08 EP EP04767620A patent/EP1648496B1/fr active Active
- 2004-07-08 JP JP2006518297A patent/JP4925822B2/ja not_active Expired - Fee Related
- 2004-07-08 ES ES04767620T patent/ES2382934T3/es active Active
- 2004-07-08 WO PCT/FR2004/001788 patent/WO2005004901A1/fr active Application Filing
- 2004-07-08 US US10/563,620 patent/US7727743B2/en active Active
- 2004-07-08 AU AU2004255503A patent/AU2004255503B2/en not_active Ceased
- 2004-07-08 AT AT04767620T patent/ATE546155T1/de active
- 2004-07-08 CA CA2531419A patent/CA2531419C/fr not_active Expired - Fee Related
- 2004-07-08 BR BRPI0412441-3A patent/BRPI0412441A/pt not_active Application Discontinuation
-
2005
- 2005-12-27 IL IL172844A patent/IL172844A/en not_active IP Right Cessation
-
2011
- 2011-09-26 JP JP2011209633A patent/JP5719266B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
ATE546155T1 (de) | 2012-03-15 |
US20060247426A1 (en) | 2006-11-02 |
JP2012051895A (ja) | 2012-03-15 |
JP4925822B2 (ja) | 2012-05-09 |
CA2531419A1 (fr) | 2005-01-20 |
FR2857267A1 (fr) | 2005-01-14 |
WO2005004901A1 (fr) | 2005-01-20 |
JP5719266B2 (ja) | 2015-05-13 |
AU2004255503B2 (en) | 2010-12-16 |
ES2382934T3 (es) | 2012-06-14 |
EP1648496B1 (fr) | 2012-02-22 |
EP1648496A1 (fr) | 2006-04-26 |
IL172844A0 (en) | 2006-06-11 |
PL1648496T3 (pl) | 2012-07-31 |
AU2004255503A1 (en) | 2005-01-20 |
FR2857267B1 (fr) | 2006-03-10 |
US7727743B2 (en) | 2010-06-01 |
DK1648496T3 (da) | 2012-05-07 |
IL172844A (en) | 2011-11-30 |
JP2007516187A (ja) | 2007-06-21 |
BRPI0412441A (pt) | 2006-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL172844A0 (en) | Method for stabilizing a cryoprecipitate of plasmatic proteins for being subjected to a viral inactivation thermal treatment | |
AU2002305450A1 (en) | Proteomimetic compounds and methods | |
JPS56135418A (en) | Heat treatment of aqueous solution containing 8 factor of coagulation of blood derived from human | |
MXPA04000368A (es) | Formulaciones enterales. | |
NO20050490L (no) | 2'-C-metyl-3'-O-L-valinester ribofuranosylcytidin for behandling av flaviviridae infeksjoner | |
DE602004031134D1 (de) | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa | |
PL371736A1 (en) | Method for administering glp-1 molecules | |
EA200401525A1 (ru) | Способы лечения гепатита (варианты ) | |
CY1109661T1 (el) | 5-cnac ως παραγοντας για χορηγηση απο το στομα τμηματων παραθορμονης | |
WO2004091497A3 (fr) | Methodes et compositions pouvant augmenter la capacite de travail anaerobie dans des tissus | |
DE60319083D1 (de) | Pharmazeutische verbindung und methoden zur behandlung von menschlichen karzinomen mittels arginin entzug | |
DK1201137T3 (da) | Cystein-/glycinrige peptider | |
WO2004054607A3 (fr) | Proteines therapeutiques stables | |
ES2340842T3 (es) | Anticuerpos anti-apc no neutralizantes. | |
DE60204224D1 (de) | Verwendung bestimmter substituierter pyrrolidone wie z.b. piracetam bei der behandlung von viralen und anderen erkrankungen | |
AU2003211474A1 (en) | Stabilized albumin preparaions | |
NO993407L (no) | Fremstilling av proteinpreparater med nedsatt aggregatinnhold | |
NO20051159L (no) | Preparater og fremgangsmater for behandling av sykdommer som viser feilsammensetting av aggregering av protein | |
PL1636261T3 (pl) | Białka trombopoetynowe o ulepszonych właściwościach | |
WO2003093419A3 (fr) | Prevention de lymphoedeme secondaire avec un adn de vegf-d | |
ATE395073T1 (de) | Behandlung von nicht-alkoholischer steatotischer hepatitis (nash) | |
DE69632629D1 (de) | Thrombin zusammensetzung | |
AU2003234342A1 (en) | Ablated slam-dependent entry | |
DK1341813T3 (da) | Anvendelse af L-carnitin som stabiliseringsmiddel af proteiner | |
FI96918B (fi) | Koostumus veriplasman stabiloimiseksi pastöroinnin aikana |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20220301 |
|
MKLA | Lapsed |
Effective date: 20200831 |